High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

Pedrazzoli P., Ledermann J. A., Lotz J. -., Leyvraz S., Aglietta M., Rosti G., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.17, sa.10, ss.1479-1488, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 17 Sayı: 10
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1093/annonc/mdl044
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1479-1488
  • Anahtar Kelimeler: high dose chemotherpy, solid tumors, stem cell transplantation, BONE-MARROW-TRANSPLANTATION, COLONY-STIMULATING FACTOR, BLOOD PROGENITOR CELLS, SOFT-TISSUE SARCOMA, PHASE-II TRIAL, PERIPHERAL-BLOOD, LUNG-CANCER, SALVAGE TREATMENT, INTENSIVE CHEMOTHERAPY, CONVENTIONAL CHEMOTHERAPY
  • Ankara Üniversitesi Adresli: Evet

Özet

Since the early 1980s high dose chemotherapy with autologous hematopoietic stem cell support was adopted by many oncologists as a potentially curative option for solid tumors, supported by a strong rationale from laboratory studies and apparently convincing results of early phase II studies. As a result, the number and size of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) to prove or disprove its value was largely insufficient. In fact, with the possible exception of breast carcinoma, the benefit of a greater escalation of dose of chemotherapy with stem cell support in solid tumors is still unsettled and many oncologists believe that this approach should cease. In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas.